Heart transplantation is a recognized treatment for advanced heart failure improving survival and quality of life.^[@R1]-[@R4]^ Survival after transplantation has improved from 1 week after the first procedure in 1967 to a median of over 10 years,^[@R5]^ and some patients have now survived over 30 years.^[@R6]^ This has been attributed to improvements in donor management,^[@R7],[@R8]^ organ preservation techniques,^[@R9]^ pharmacological immunosuppression,^[@R10]-[@R12]^ and diagnosis of rejection.^[@R13]^

Postoperative cardiac allograft dysfunction may result in a low cardiac output (CO) syndrome requiring prolonged inotropic or mechanical circulatory support and possible re-transplantation.^[@R14]^ In the absence of an alloimmune response or technical issue affecting the transplant, this is described as primary allograft dysfunction (PGD), and more severe cases, resulting in death, are described as primary graft failure (PGF).

The PGD remains an important problem after heart transplantation; it is reported to have an incidence up to 40%^[@R15]--[@R21]^ and is responsible for up to 40%, of deaths within 30 days,^[@R16],[@R22],[@R23]^ and 18% of deaths between 31 days and 1 year after transplantation.^[@R16],[@R19],[@R24]^ The variation in incidence between studies may be partly due to the lack of a standardised definition of PGD.

The occurrence of PGD in donor hearts that appeared to have acceptable function before organ retrieval may be explained by the cumulative effect of a series of injuries associated with retrieval, transportation, and during and after implantation. Brain stem death in the donor affects cardiac function by mechanisms that include the catecholamine storm^[@R25],[@R26]^ and hemodynamic changes that cause myocardial stress, particularly transient severe hypertension. These effects are compounded by subsequent hypotension, reduced coronary perfusion, the therapeutic use of exogenous catecholamines, and an evolving proinflammatory milieu.^[@R25],[@R27]--[@R31]^ Although the impact of myocardial ischemia during organ retrieval is reduced by cardioplegic cardiac arrest and cooling, myocardial injury and dysfunction still develop in a time-dependant fashion.^[@R19],[@R22],[@R32]^ Further injury occurs during implant surgery, especially during cardiac reperfusion, followed by the impact of an innate immune response in the recipient.^[@R33],[@R34]^

Although PGF represents the lethal form of PGD, PGD may also lead to death indirectly through secondary organ failure or complications of therapy. Multiorgan failure and renal failure cause 14% and 0.6% of deaths within 30 days of transplantation, respectively, and both may be a consequence of PGD.^[@R24]^ In addition, some PGD deaths may be misclassified as being due to right heart failure secondary to recipient pulmonary hypertension.^[@R23],[@R35]--[@R39]^ Consequently, the magnitude of the impact of PGD on the outcome of heart transplantation remains poorly defined.

The purpose of this study was to evaluate in a prospective manner the use of a proposed definition of PGD based on clinical parameters in the first 72 hours after transplantation.

MATERIALS AND METHODS
=====================

As part of a United Kingdom-based prospective study, funded by the British Heart Foundation, titled the Heart Evaluation And Retrieval for Transplantation (HEART) study, clinical and physiological data from consecutive donors of transplanted hearts and the corresponding recipients were collected from March 2007 to November 2011. The study had received ethics approval from a national multicenter research ethics committee Scotland (ref 05/MRE00/66).

Consent for the study was sought from the next of kin, and donor data were collected prospectively by the donor transplant co-ordinators for NHS Blood and Transplant, where data were compiled and validated before forwarding to our study center. Recipient data were collected by recipient transplant co-ordinators at each of the 6 U.K. heart transplant centers. We defined PGD as "A severe impairment of systolic graft function affecting the right, left, or both ventricles accompanied by hypotension, low CO, and high filling pressures, that is, pulmonary capillary wedge pressure (PCWP) greater than 18 mm Hg or a more than 30% increase in PCWP and a cardiac index (CI) less than 2.5 L/min per m^2^ or more than 30% decrease in CI within the first 72 hours", in the absence of technical complications, (including tamponade) and hyper acute rejection.

After applying this definition to the national cohort of heart transplants, we validated it against the clinical outcome of the transplant; including recipient inotrope requirements, the need for an intra-aortic balloon pump (IABP) or other mechanical circulatory support and also evaluated its consequences in terms of need for renal replacement therapy, length of intensive care unit stay, and mortality at 30 days 1 year, and 3 years.

Data were summarized as mean and standard deviation (SD) or median and interquartile range, as appropriate. Transplants with and without PGD were compared using the Student *t* test or the Wilcoxon test, as appropriate. Binary outcomes were assessed using the χ^2^ test or Fisher exact test if expected frequencies were less than 5, and time to event outcomes were analyzed using survival methods and evaluated using a log rank test. For length of stay, patients who died before hospital discharge were treated as censored observations. Inotrope scores were compared by fitting a generalized linear model which allowed for the correlation between scores measured at repeated time points after transplantation. The inotrope scores were highly skewed and a γ model with reciprocal link provided the best fit to the data (after excluding 2 extreme outlying values).

Drugs dosages were converted to μg/kg per minute to calculate an inotrope score. This was defined as: "Dopamine (dose × 1) + Dobutamine (dose × 1) + Amrinone (dose ×1) + Milrinone (dose × 15) + Epinephrine (dose ×100) + Norepinephrine (dose × 100) + Enoximone (dose × 1) + Isoprenaline (dose × 100)".^[@R40]--[@R43]^

At a recent consensus group meeting on PGD at the 2013 International Society for Heart and Lung Transplantation annual meeting in Montreal, a definition of PGD and its grading was proposed.^[@R44]^ Therefore, we attempted to retrospectively classify our PGD cases according to the proposed grades and examine the survival by PGD grade. Three PGD grades were proposed based on left ventricular function. Mild PGD (grade 1); left ventricular ejection fraction (LVEF) 40% or lower or hemodynamics with right atrial (RA) pressure greater than 15 mm Hg, PCWP less than 20 mm Hg, CI less than 2.0 L/minute per m^2^ (\>1 hr) and low-dose inotropes (score \< 10). Moderate PGD (grade 2); LVEF 40% or lower and hemodynamics with RA greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less than 2.0(\>1 hour) plus inotrope score 10 or higher, or newly placed IABP. Severe PGD (grade 3); dependant on left or biventricular mechanical support including extra corporeal membrane oxygenation (ECMO), left ventricular assist device, biventricular assist device or percutaneous left ventricular assist device except IABP.

To apply a similar grading system to our study data, we considered the requirement for IABP, VAD, and ECMO and calculated the inotrope score in the first 72 hours after transplantation. We had prospectively collected inotrope usage, and 6, 24, 48, and 72 hours after transplantation, this allowed us to calculate an inotrope score at each time point. Using this score and the utilization of IABP, VAD, ECMO, we divided our PGD cohort into grades 2 and 3, based on the inotrope scores and mechanical support as outlined in the PGD-Primary allograft dysfunction-The International Society for Heart and Lung Transplantation (PGD-ISHLT) definition, but over the first 72 hours after transplantation instead of just 24 hours.

RESULTS
=======

A total of 528 transplants in 520 recipients were performed using hearts from adult donors (aged 16 years or older) during the study period. Of these 528 transplants, donor family consent for the study was given for 314 (59%) (Figure [1](#F1){ref-type="fig"}), data were not submitted for 11 of these hearts, 10 were transplanted as heart lung blocks, and 3 were a second transplantation carried out within 72 hours of the first; these second heart transplantations were excluded. For the 3 recipients of 2 hearts within 72 hours, the first transplant was considered to have PGD and the recipient classified as having developed PGD regardless of the outcome of the second heart. Of the 301 heart only transplants in the study cohort, 8 were second transplants, the recipients having received their first transplant before the study started (time from first to second transplant ranged from 66 to 2758 days); these were included in the study. Centers classified the recipient as having developed PGD using our prespecified definition, and this was reported to us for 290 of the 301 transplants (see Figure [1](#F1){ref-type="fig"}). Of the 290 transplant recipients, 94 developed PGD (32.4%; 95% confidence interval, 27.0% to 38.1%), 8 of whom died within 72 hours from PGF.

![Flowchart showing the total number of heart transplants nationally and recruitment to the HEART study.](tp-99-1919-g001){#F1}

Descriptive donor and recipient characteristics of the study cohort are summarized in Table [1](#T1){ref-type="table"}.
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Donor and recipient characteristics

![](tp-99-1919-g002)

We evaluated the clinical significance of PGD identified by our definition. Inotropes scores were similar at 6 hours but were significantly higher in the PGD group 24, 48, and 72 hours after transplantation (Table [2](#T2){ref-type="table"}). As might be expected, the incidence of prolonged inotropes usage (\>72 hours) was higher in the PGD group (75% vs 21%, *P* \< 0.01) as was the requirement for an IABP (50% vs 15%, *P* \< 0.01), mechanical circulatory support (29% vs 0%, *P* \< 0.01), and the incidence of postoperative renal failure requiring replacement therapy (61% vs 26% *P* \< 0.01). The median length of intensive care unit stay was longer in the PGD group (14 vs 5 days, *P* \< 0.01). The risk of death was almost 4 times greater in the PGD group compared to the non-PGD group (hazard ratio, 3.9; 95% confidence interval, 2.4-6.2; *P* \< 0.01; Table [3](#T3){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). When we looked retrospectively at the severity of PGD according to the recently proposed PGD-ISHLT grading system, early mortality was related to PGD severity, PGD-ISHLT grade 3 had the highest mortality, followed by grade 2, whereas the mortality of PGD-ISHLT grade 1 was similar to that of those without PGD (Figure [2](#F2){ref-type="fig"}). Late mortality in those who survived to discharge was not different in those with or without PGD (*P* = 0.81). Also, ISHLT-PGD grade did not influence postdischarge survival (*P* = 0.85)
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Inotrope scores in first 72 hours after transplantation
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###### 

Recipient outcomes by PGD

![](tp-99-1919-g004)

![Recipient mortality to 3 years by PGD and PGD grade. Grade 1, n = 21; grade 2, n = 46; grade 3, n = 27.](tp-99-1919-g005){#F2}

DISCUSSION
==========

We found that our prespecified definition of PGD could be applied effectively by the transplant coordinators in the recipient centres and that the identification of PGD was associated with differences in morbidity and mortality. Our overall incidence for PGD was 32%, which is consistent with that reported previously.^[@R17]--[@R19],[@R24]^ The 30-day mortality rate among the PGD population was 37% confirming the mortality reported by others.^[@R22]^

When this study was conceived, a standardized definition of PGD had not been established, the consensus from the definitions used in the literature was that PGD is a state of a low CO and raised filling pressures (excluding hypovolemia) after heart transplantation requiring prolonged inotropic support^[@R21],[@R22],[@R45]--[@R47]^ and sometimes mechanical circulatory support where there is no evidence of a technical surgical complication, including tamponade, or of alloimmune rejection, including hyperacute antibody-mediated rejection.^[@R17],[@R21],[@R22],[@R45],[@R48]^ The various definitions of PGD used in the literature have resulted in divergent assessments of its impact on survival and complications. Definitions based on inotrope requirements and CO status tend to include a broader spectrum of patients, whereas those restricted to the need for mechanical support or death report a lower incidence and a worse outcome.^[@R19]^

Our definition was developed through a consensus between U.K. transplant centers, and its implementation was preceded by education of recipient coordinators, resulting in its standard application. Recipient clinical data in the first 72 hours was collected prospectively solely for the purpose for the study and the transplant recipient coordinators received guidance and access to the core study group using a 24-hour helpline to support accurate data collection.

When this study commenced in 2007, we could not have anticipated the recently proposed definition of PGD by ISHLT (PGD-ISHLT). That definition is conceptually similar to the one used here but it also grades the severity of PGD. The ISHLT group suggested that the definition of primary PGD should be based on left ventricle and right ventricle dysfunction within the first 24 hours with the exclusion of secondary graft dysfunction due to hyper acute rejection, pulmonary hypertension with right ventricle failure, or surgical complication.^[@R44]^

We have evaluated prospectively our definition in a national prospective study lasting 4 years and 8 months. To our knowledge, this is the first study to prospectively validate a definition of PGD with multicenter data. Our definition covered the first 72 hours in contrast to PGD-ISHLT which was limited to 24 hours. Because we did not record the specific time point at which PGD was diagnosed within the 72 hours, we are unable to use our data to validate the ISHLT-PGD definition.

The ISHLT group proposed that the use of inotropes be incorporated into their definition. We did not include an inotrope score in our definition but we found that our PGD group had a higher inotrope score and more prolonged use of inotropes, suggesting that the 2 definitions are likely to identify similar patients.

Our study has strengths and limitations. Data were collected nationally in a prospective manner during a period when clinical practices did not change significantly. The number of heart transplants included was large compared with previous studies. The study included all donor hearts from whom consent was obtained, thereby minimizing the risk of selection bias. The criteria and mechanisms for allocation of donor organs, preservation (St Thomas\'s solution in most of cases) and transportation were standardized and monitored by the Cardiothoracic Transplant Advisory Group, of NHS Blood and Transplant. We believe that PGD is a syndrome that may take more than 24 hours to evolve fully and therefore, the use of data up to 72 hours may have increased the sensitivity of our definition for identifying PGD. Our definition did not rely on echocardiography-derived LVEF, which is sometimes difficult to obtain in the immediate postoperative period and is an operator dependant investigation.

The evaluation of risk factors for PGD was outside the scope of this study. We did not collect raw data on recipient RA pressure, PCWP, pulmonary artery systolic pressure, and echocardiography-derived LVEF at regular intervals during the 72 hours period, this may have reduced the sensitivity of our definition.

The ISHLT group proposed grading PGD based on inotrope score, use of IABP, and mechanical circulatory support. Because of the lack of raw rata on LVEF, RA pressure PCWP, CI on an hourly basis, we could not divide our heart transplant population into those with and without PGD strictly by the proposed ISHLT definition; as a result, we were limited to a modified grading based on inotrope score and mechanical support. We attempted to retrospectively grade our PGD cases in a similar though not identical fashion, we considered the requirement for IABP, VAD (levitronix-like device), ECMO, and calculated the inotrope score in the first 72 hours after transplantation. In this manner, we divided our PGD cohort into grades 1, 2, and 3. We found that a higher PGD grade was associated with increased mortality; however, there were a small number of grade 1 PGD cases (n = 21), and these had a similar mortality rate to the non-PGD recipients (Figure [2](#F2){ref-type="fig"}).

A clinical definition of PGD should help predict or relate to clinical outcome. Patients meeting our definition of PGD had increased morbidity (return to theatre, renal requirement, and longer intensive therapy unit (ITU) stay). These have been associated with poorer overall outcomes in cardiac surgery. In other studies, the return to theatre for re-sternotomy in cardiac surgery has been shown to be associated with increased mortality, length of ITU stay, inotrope requirements, and morbidity.^[@R49]--[@R52]^ The development of renal failure after cardiac surgery has been demonstrated to be associated with increased mortality and morbidity.^[@R53]--[@R58]^ Further, our PGD cohort had a longer ITU stay which has also been associated with a poorer outcome.^[@R59]--[@R61]^ As a result, PGD has a significant impact on the cost and cost-effectiveness of heart transplantation.

Our robust and easy to apply definition of PGD, which has been prospectively tested and related to outcome may enable clinicians to better assess and identify risk factors for PGD and could provide a suitable endpoint for future studies of donor management, organ protection and matching, and in resource planning. It may also be of use in quality assurance and audit.

In conclusion, our definition of PGD was able to be applied prospectively in a national multicenter study, and the cases it defined had increased mortality, ITU length of stay, and postoperative complications. Our data also support a grading of the severity of PGD similar to that proposed by the ISHLT consensus group.
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